| inactivated poliovirus vaccine | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
|---|---|
| inactivated polio vaccine | <pharmacology, virology> An inactivated vaccination, administered by injection to children for protection against the polio virus. Typically given at 2, 4 and 15 months. A final vaccine is recommended at 4-6 years. (27 Sep 1997) |
| poliovirus vaccine | A suspension of formalin-inactivated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used in the united states only for immunization of immunologically deficient patients and for primary immunization of unimmunised adults at risk. (12 Dec 1998) |
| poliovirus vaccine, oral | A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (12 Dec 1998) |
| oral poliovirus vaccine | An aqueous suspension of live, attenuated strains of poliomyelitis virus (types 1, 2, and 3) given orally for active immunization against poliomyelitis. See: Sabin vaccine. Synonym: poliomyelitis vaccines. (05 Mar 2000) |
| live oral poliovirus vaccine | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| Allen video enhanced contrast | <procedure> A method for enhancing microscopic images pioneered by R D Allen. The digitised image has the background (an out of focus image of the same microscopic field with comparable unevenness of illumination etc.) subtracted and the contrast expanded to utilise the potential contrast range. Interestingly, it is possible to produce images of objects that are below the theoretical limit of resolution microtubules for example. (18 Nov 1997) |
| potency | Power, especially: 1. <gynaecology> The ability of the male to perform sexual intercourse. 2. <pharmacology> The power of a medicinal agent to produce the desired effects. 3. <anatomy> The ability of an embryonic part to develop and complete its destiny. Origin: L. Potentia = power (14 May 1997) |
| sexual potency | The ability to carry out and consummate sexual intercourse, usually referring to the male. (05 Mar 2000) |
| vaccines, inactivated | Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. (12 Dec 1998) |
| inactivated serum | <immunology> Serum that has been heated 50캜 for 30 minutes to destroy the lytic activity of complement. (05 Mar 2000) |
| poliovirus | <virology> A member of the enterovirus group of Picornaviridae that causes poliomyelitis. (18 Nov 1997) |
| poliovirus hominis | The picornavirus (genus Enterovirus) causing poliomyelitis in humans; the route of infection is the alimentary tract, but the virus may enter the bloodstream and nervous system, sometimes causing paralysis of the limbs and, rarely, encephalitis; many infections are inapparent; serologic types 1, 2, and 3 are recognised, type 1 being responsible for most paralytic poliomyelitis and most epidemics. Synonym: poliovirus hominis, poliovirus. (05 Mar 2000) |
| poliovirus vaccines | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| acellular vaccine | <immunology, pharmacology, virology> Vaccine consisting of antigenic parts of cells. (13 Nov 1997) |